NEW YORK, Aug. 30, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Intellipharmaceutics International Inc. (NASDAQ:IPCI) who purchased shares between January 14, 2016 and July 26, 2017.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) Intellipharmaceutics failed to conduct a human abuse liability study to support its Rexista New Drug Application (“NDA”); (2) the Company did not include abuse-deterrent studies conducted to support abuse-deterrent label claims related to abuse of the drug by various pathways; (3) the Company was not submitting sufficient data to support approval of the NDA; and (4) as a result, Defendants’ statements about Intellipharmaceutics’ business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
If you suffered a loss in Intellipharmaceutics you have until September 29, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sbm/intellipharmaceutics-international-inc?wire=3.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com


MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Apple Turns 50: From Garage Startup to AI Crossroads
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
Britain Courts Anthropic Amid US Defense Department Dispute
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 



